A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer

Nicholas Spetsieris, Myrto Boukovala, Justin A. Weldon, Alexandros Tsikkinis, Anh Hoang, Ana Aparicio, Shi Ming Tu, John C. Araujo, Amado J. Zurita, Paul G. Corn, Lance Pagliaro, Jeri Kim, Jennifer Wang, Sumit K. Subudhi, Nizar M. Tannir, Christopher J. Logothetis, Patricia Troncoso, Xuemei Wang, Sijin Wen, Eleni Efstathiou

Research output: Contribution to journalArticlepeer-review

Abstract

The Src pathway and neoangiogenesis have been implicated in prostate cancer progression. In an open-label randomized phase 2 study, no difference was reported in overall survival or time to treatment failure between dasatinib and sunitinib combined with abiraterone after disease progression while receiving abiraterone monotherapy in patients with bone metastatic castration-resistant prostate cancer.

Original languageEnglish (US)
JournalClinical Genitourinary Cancer
DOIs
StateAccepted/In press - 2020

Keywords

  • Androgen-signaling inhibition
  • Neoangiogenesis
  • Src pathway
  • Targeted agents
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Urology

Fingerprint Dive into the research topics of 'A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.

Cite this